Clinical trials: Normal Population
Erythematotelangiectatic Rosacea
Dose-Finding Study of CD07805/47 Topical Gel in Subjects With Erythematotelangiectatic Rosacea
This is a randomized, double-blind, parallel-group, vehicle-controlled, dose-finding study to investigate the pharmacodynamics and the safety of three dosages of CD07805/47 topical gel (0.07%, 0.18%, and 0.50%), after a single…
- Trial name
- NCT00989014
- Testing
- CD07805/47
- Where
- 5 sites in United States
- Volunteers
- 122 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
CAPTAIN-AD: Clinical Study of AmorePacific's TRPV1 Antagonist in Atopic Dermatitis
This is a phase III study to investigate the safety and efficacy of PAC-14028 cream in Atopic Dermatitis patients.
- Trial name
- NCT02965118
- Testing
- PAC-14028 cream 1.0%, PAC-14028 cream Vehicle
- Where
- South Korea
- Volunteers
- 240 people
- Sponsor
- Amorepacific Corporation
Atopic Dermatitis
Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD
This is a Phase 2 randomized, double-blind, parallel group, vehicle-controlled study to evaluate the safety and efficacy of topical ATx201 OINTMENT in adolescents and adults with mild to moderate Atopic Dermatitis
- Trial name
- NCT04339985
- Testing
- ATx201, ATx201 OINTMENT vehicle
- Where
- 10 sites in Bulgaria, Denmark and 1 more
- Volunteers
- 220 people
- Sponsor
- UNION therapeutics
Actinic Keratoses, Skin Neoplasms
ALA-PDT Versus Vehicle PDT for Treatment of AK and Reduction of New NMSC in Solid Organ Transplant Recipients
The purpose of this study is to determine and compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) versus vehicle PDT (VEH-PDT) in the treatment of actinic keratoses (AK) and…
- Trial name
- NCT00865878
- Testing
- Aminolevulinic Acid, Vehicle
- Where
- 7 sites in United States
- Volunteers
- 6 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Rheumatoid Arthritis (RA)
A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate
The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of ASP5094 in patients with rheumatoid arthritis (RA) treated with background methotrexate (MTX).
- Trial name
- NCT03257852
- Testing
- ASP5094, Methotrexate therapy
- Where
- 31 sites in Japan
- Volunteers
- 66 people
- Sponsor
- Astellas Pharma Inc
Alopecia Areata
Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia Areata
This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03941548
- Testing
- CTP-543
- Where
- 12 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Concert Pharmaceuticals
Neoplasms, Breast
Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
This phase II study will evaluate and compare the efficacy and tolerability of two dose schedules (1500 mg QD and 500 mg BID) of oral Lapatinib as treatment for patients with advanced or metastatic breast cancer.
- Trial name
- NCT00089999
- Testing
- Lapatinib
- Where
- 31 sites in United States, Chile and 9 more
- Volunteers
- 138 people
- Sponsor
- GlaxoSmithKline
Psoriasis
Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis.
- Trial name
- NCT03850483
- Testing
- PF-06700841
- Where
- 79 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis
This study will evaluate the safety \& efficacy of Certolizumab Pegol (CZP) as additional medication to Methotrexate (MTX) in Chinese subjects with Rheumatoid Arthritis.
- Trial name
- RAPID-C (NCT02151851)
- Testing
- Certolizumab Pegol, Methotrexate
- Where
- 30 sites in China
- Volunteers
- 430 people
- Sponsor
- UCB Pharma SA, Belgium
Lower Extremity Chronic Ulcers in Diabetics
Evaluation of CureXcell® in Treating Lower Extremity Chronic Ulcers in Adults With Diabetes
Chronic foot ulcers are particularly prevalent in patients with underlying diabetes mellitus. These ulcers are reported to be the leading cause of hospitalization among people with diabetes.
- Trial name
- NCT01421966
- Testing
- CureXcell®
- Where
- 37 sites in United States, Canada and 1 more
- Volunteers
- 285 people
- Sponsor
- Macrocure Ltd.
Psoriatic Arthritis
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis
The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).
- Trial name
- NCT06624228
- Testing
- Bimekizumab, Risankizumab
- Where
- 127 sites in United States, Australia and 9 more
- Volunteers
- 553 people
- Sponsor
- UCB Biopharma SRL
Common Wart
A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts
The primary objective of this study is to evaluate the effectiveness of A-101 compared to Vehicle when applied to 1 Target common wart on the trunk or extremities twice a week.
- Trial name
- NCT03278028
- Testing
- A-101 Topical Solution, A-101 Vehicle Solution
- Where
- 16 sites in United States
- Volunteers
- 159 people
- Sponsor
- Aclaris Therapeutics, Inc.
Acne Vulgaris
A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris
EPIDUO™ (adapalene and benzoyl peroxide) Gel 0.1%/2.5%, marketed by GALDERMA LABORATORIES, L.P., is a safe and effective topical therapy used for the treatment of acne vulgaris.
- Trial name
- NCT01501799
- Testing
- adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO
- Where
- 25 sites in United States, Belize and 1 more
- Volunteers
- 885 people
- Sponsor
- Actavis Mid-Atlantic LLC
Hair Health, Hair Loss
A Single-Group Clinical Trial Investigating the Effects of a Hair Vitamin Combination on Hair Growth and Hair Health
This clinical trial aims to investigate the effectiveness of two Vitamins Revive hair supplements in promoting hair growth, reducing hair loss, and improving overall hair health.
- Trial name
- NCT06120933
- Testing
- Hair Nutra Growth Supplement & Hair Nutra Boost Supplement, Hair Nutra Growth
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- BrandiZone
Atopic Dermatitis, Eczema
Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)
The purpose of this study is to evaluate the efficacy and safety of three concentrations of a development drug compared to ointment base (vehicle) in subjects with Atopic Dermatitis (AD).
- Trial name
- NCT01359787
- Testing
- Mapracorat, Vehicle without active
- Where
- Germany
- Volunteers
- 197 people
- Sponsor
- Bayer
Sprain, Strain
Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Ankle Sprain or Strain
The purpose of this study is to evaluate the effect of a ketoprofen topical patch on the pain associated with ankle sprain or strain.
- Trial name
- NCT00351104
- Testing
- Ketoprofen Topical Patch 20%
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Alkemira SA
Systemic Sclerosis, Ulcers
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
The DUAL-1 study is designed as a multicenter, double-blind two-period study with an initial fixed 16-week Period 1, followed by a Period 2 of variable duration.
- Trial name
- DUAL-1 (NCT01474109)
- Testing
- macitentan 3mg, macitentan 10mg
- Where
- 77 sites in United States, Australia and 16 more
- Volunteers
- 289 people
- Sponsor
- Actelion
Sjogren Syndrome, Mixed Connective Tissue Disease
A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD)
This study was a basket trial designed to establish safety, tolerability and efficacy of MHV370 in Sjögren's Syndrome (SjS) and Mixed Connective Tissue Disease (MCTD).
- Trial name
- NCT04988087
- Testing
- MHV370
- Where
- 10 sites in China, Germany and 4 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Generalized Epidermolysis Bullosa Simplex
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
The proposed Phase 2/3 trial with double-blind and open-label extension phases is an international, multicenter study designed to assess the efficacy and safety of diacerein 1% ointment in patients with generalized EBS.
- Trial name
- EBShield (NCT06073132)
- Testing
- AC-203, Vehicle
- Where
- 30 sites in United States, Australia and 16 more
- Volunteers
- 80 people
- Sponsor
- TWi Biotechnology, Inc.
HIV
Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function
The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of oral bictegravir (formerly GS-9883) in adults with impaired renal function relative to matched, healthy controls with normal renal function.
- Trial name
- NCT02400307
- Testing
- Bictegravir
- Where
- 7 sites in United States, New Zealand
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.